Retraction
Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
Paper Information
Record ID:
46194
Author(s):
Publication Date:
October 14, 2021
Retraction Date:
June 21, 2023
(2.4 years years ago)
Subjects:
Institution:
Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xian 710068, ChinaCountry:
🇨🇳 ChinaArticle Type:
Publisher:
Hindawi
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1155/2023/9843134Additional Notes:
See also: https://pubpeer.com/publications/5C3B875B43DEFA8FB5D5E6FA1E7949
Citations (4)
4
Total Citations1
Post-Retraction(25.0%)
2
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
1
Within 1 year
0
After 2+ years
121
Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer
Jintao Mi, Hongsheng Zhang, Weiwei Cao et al. (4 authors)
Medicine
Open Access
Published: Oct 2023
6 citations
6 citations
121 days after retraction
Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression
Qi Wang, Lin Zhang, Zhenzhong Su et al. (6 authors)
Pulmonary Pharmacology & Therapeutics
Published: Jun 2023
10 citations
10 citations
5 days before retraction
Retracted: Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
Evidence-Based Complementary and Alternative Medicine
Evidence-based Complementary and Alternative Medicine
Open Access
Published: Jan 2023
2 citations
2 citations
171 days before retraction
Quick Stats
Total Citations:
6
Years Since Retraction:
2.4 years
Open Access:
Yes
Last Checked:
Jul 24, 2025